No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications
FDA is investigating reports of hair loss, aspiration, and suicidal thoughts among people taking the medications
Dulaglutide effective in preventing substantial weight gain, which was more common in women
Autism, substance-related disorders, disruptive disorders were diagnoses with highest rates of pharmacologic restraint days
Higher doses of prescription psychostimulants, treatment duration positively linked to longer retention
4 percent increase in risk for CVD seen in association with each one-year increase in ADHD meds across 14 years of follow-up
One of five trials in the FDA review was positive; all three trials in the published literature were positive
Rapid induction to extended-release buprenorphine 300-mg injection feasible and well tolerated for those using fentanyl
Zurzuvae not only presents a new way to treat postpartum depression, but it also 'appears to be fast-acting'
Intravenous ketamine delivered during surgical anesthesia has no greater effect than placebo in reducing severity of depression